How does SLT compare to eye drops for glaucoma treatment? Prof. Gus Gazzard (UK), chief investigator of the LiGHT Trial, reveals eye-opening findings on IOP reduction, disease progression, and adherence. With SLT showing 100% compliance, this raises critical questions about the future of glaucoma care. Explore these insights during Glaucoma Awareness Month.
![[Internal] Data Visualization Video Dr. Gus Gazzard thumbnail Science Saves Sight Prof. Gus Gazzard on SLT vs. Drops for Glaucoma and IOP Control](https://staging.cake.bantampoint.org/wp-content/uploads/sites/3/2025/01/Internal-Data-Visualization-Video-Dr.-Gus-Gazzard-thumbnail-Science-Saves-Sight-Prof.-Gus-Gazzard-on-SLT-vs.-Drops-for-Glaucoma-and-IOP-Control.jpg)
